Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Aim: To investigate the impact of triglyceride on hypertriglyceridemic acute pancreatitis (HTG-AP) and different lipid-lowering methods on triglyceride-lowering efficiency and HTG-AP.
Methods: The patients with HTG-AP from January 2012 to December 2023 in Civil Aviation General Hospital were analyzed, retrospectively. Patients were divided and compared according to whether their triglycerides were below 5.56 mmol/L at 48 and 72 h of admission. The patients were divided into control group, insulin group, and low molecular weight heparin (LMWH)+bezafibrate group based on the different methods of lipid-lowering. Propensity score matching (PSM) was employed to balance the baseline characteristics.
Results: There was no correlation between the severity of HTG-AP and the triglyceride at admission. The incidence of severity, local complications, and persistent organ failure (POF) were significantly decreased in patients with 48-h and 72-h triglyceride attainment. Following PSM, the incidence of infectious pancreatic necrosis (IPN) (3.3% vs. 13.3%) was significantly reduced in insulin group compared with control group ( < .05). Compared with control group, LMWH + bezafibrate group had higher lipid reduction efficiency, and the incidence of IPN (0.9% vs. 10.1%) and POF (8.3% vs. 19.3%) was significantly decreased ( < .05). There was no significant difference in the efficiency of lipid-lowering, complications, and POF between LMWH + bezafibrate group and insulin group ( > .05).
Conclusion: The severity of HTG-AP is not associated with the triglyceride levels at admission. However, rapid reduction of triglyceride levels can lower the incidence of local complications and respiratory failure. Compared with conservative treatment, insulin and LMWH + bezafibrate can both reduce the incidence of IPN in patients with HTG-AP.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/00365521.2024.2342406 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Statins in Acute Ischemic Stroke: Mechanisms, Resistance, and Precision Strategies for Neurovascular and Cognitive Protection.
CNS Drugs
September 2025
Global Health Neurology Lab, Sydney, NSW, 2150, Australia.
Acute ischemic stroke (AIS) remains a leading cause of mortality and long-term disability globally, with survivors at high risk of recurrent stroke, cardiovascular events, and post-stroke dementia. Statins, while widely used for their lipid-lowering effects, also possess pleiotropic properties, including anti-inflammatory, endothelial-stabilizing, and neuroprotective actions, which may offer added benefit in AIS management. This article synthesizes emerging evidence on statins' dual mechanisms of action and evaluates their role in reducing recurrence, improving survival, and mitigating cognitive decline.
View Article and Find Full Text PDFPre-donation statin therapy to improve solid organ transplant outcomes.
Transpl Immunol
September 2025
Intensive Care, Royal Free Hospital, Hampstead, London, United Kingdom.
Background: Inflammatory injury in organ donors, particularly after brain death and during ischemia-reperfusion, contributes to graft dysfunction, rejection, and reduced survival. Statins, beyond their lipid-lowering role, exert pleiotropic anti-inflammatory and immunomodulatory effects, including IL-6 suppression, NF-κB inhibition, immune cell modulation, and potential alteration of exosome secretion.
Methods: Building upon this background, this narrative review synthesises preclinical and clinical evidence on pre-donation statin therapy in solid organ transplantation.
Neuro-cognitive profile of adult statin users at a large tertiary care hospital in Delhi, India.
JRSM Cardiovasc Dis
September 2025
Division of Reproductive, Child Health and Nutrition, Indian Council of Medical Research, Department of Health Research, Ministry of Health and Family Welfare, Government of India, New Delhi, India.
Background: Statins are the most widely prescribed drugs for dyslipidemia and CAD. But evidence on their cognitive effects is conflicting. A unique genetic makeup and variable lipid patterns make South Asians more susceptible to statin adverse effects.
View Article and Find Full Text PDFRecaticimab in adult heterozygous familial hypercholesterolemia (REMAIN-3): A multicentre, randomised, double-blind, placebo-controlled phase 3 study.
Cardiovasc Res
September 2025
Cardiovascular Medicine, Guangdong Provincial People's Hospital, Guangzhou, China.
Aims: Heterozygous familial hypercholesterolemia (HeFH) is a genetic disorder, characterised by high plasma concentrations of low-density lipoprotein cholesterol (LDL-C) from birth. This study aimed to assess the efficacy and safety of recaticimab, a new humanised anti-PCSK9 antibody capable of reducing LDL-C levels in patients with poorly controlled HeFH.
Methods And Results: REMAIN-3 was a multicentre, randomised, double-blind, placebo-controlled phase 3 study done at 25 sites in China.
The interaction between blood lipids and ASCVD increases the risk of DKD: a nonlinear relationship transforms into a linear relationship, a cross-sectional study.
Front Endocrinol (Lausanne)
September 2025
Yunnan Key Laboratory of Laboratory Medicine, Kunming, China.
Background: Atherosclerotic cardiovascular disease (ASCVD) and diabetic kidney disease (DKD) are interconnected vascular complications in diabetes, with dyslipidemia playing a key role. The modifying effect of ASCVD on the lipid-DKD relationship in diabetic patients without lipid-lowering treatment remains unclear.
Methods: This retrospective study included 26,476 type 2 diabetic patients without lipid-lowering therapy.